By Fineline Cube 
US-based Varian Medical Systems (NYSE: VAR) announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its Ethos 2.0 AI-powered integrated adaptive radiotherapy (ART) platform. This milestone marks Ethos 2.0 as the first AI-based online ART platform to achieve regulatory approval in the US, EU, and China.
Ethos 2.0 Features
Ethos 2.0 is equipped with a HyperSight wide-field eagle-eye ultra-HD imaging system, an AI-driven optimization engine, and a unified hardware-software architecture. These features significantly enhance patient comfort and treatment efficiency while enabling real-time visualization of ART dose monitoring.-Fineline Info & Tech